Ona Therapeutics, which is focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today the closing of a €30 million Series A financing, with partici...
Read moreYsios Capital, a leading biotechnology venture capital firm in Spain, today announced its third fund, Ysios BioFund III, with a committed amount of € 155M and a final target size of € 200M.
Read moreAM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company, leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human...
Read moreAura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it closed a $40 million Series D financing. New investor Medicxi led the round, with
Read morePfizer and Vivet to collaborate on development of potential breakthrough therapy for Wilson disease
Read moreVivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfize...
Read moreCataloniaBioHT also recognised the career of Antonio Parente. The awards were given out yesterday by Catalan Minister of Health Alba Vergés at the CataloniaBioHT Gala Dinner at the Sant Pau Art Nouve...
Read moreXeltis, a clinical-stage medical device company pioneering a restorative approach in heart valve therapy, today announced the completion of an oversubscribed €45 million ($52 million) Series C finan...
Read moreVivet Therapeutics (‘Vivet’), an emerging biotechnology company developing novel gene therapies for rare, inherited metabolic diseases, announced it has raised €37.5 million in a Series A financ...
Read moreThe financing was led by new investors Sofinnova Ventures and Ysios Capital, and included existing investors HealthCap, Life Sciences Partners (LSP), and Tekla Capital Management. Since its founding, ...
Read morePrimary hyperoxaluria (PH) is a rare autosomal recessive disorder leading to markedly elevated levels of endogenous oxalate causing kidney deterioration and a gradual calcification of soft tissues. If...
Read moreCorWave, a medical technology company that develops innovative mechanical circulatory support devices, has announced that it has completed a $17.1 million (€15.5M) Series B financing. Existing share...
Read more